Clinical Trials Sponsored by TripleMed B.V.

Total 1412 results

European Cardiovascular Research Center
Comed B.V.

Unknown

Hyperion™ International Registry Trial (COM-01)

Patent Ductus Arteriosus | Atrial Septal Defects

France, Germany, Algeria, China
Alloksys Life Sciences B.V.
Aix Scientifics

Completed

Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis (ALS-003-2008)

Acute Rheumatoid Arthritis

United Kingdom
Free University Medical Center
Dirinco B.V.

Completed

Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration (CASH-CVVH)

Acute Kidney Injury

Netherlands
Maastricht University Medical Center
Dirinco B.V.

Terminated

Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients

Thrombosis | Bacteremia | Hematological Malignancies

Netherlands
uniQure France SAS

Recruiting

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

Mesial Temporal Lobe Epilepsy

United States
Erasmus Medical Center
ISA Pharmaceuticals B.V.

Recruiting

Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (HEB-PEP)

Chronic Hepatitis b

Netherlands
Alloksys Life Sciences B.V.
Aix Scientifics

Recruiting

Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase (APPIRED-III)

Systemic Inflammation | Cardiopulmonary-bypass

Australia, Austria, Belgium, Germany, Italy, Malaysia, Portugal, Netherlands, Russian Federation, Singapore, Spain
University of Reading
Winclove Probiotics B.V.

Completed

Acute and Chronic Effects of Ecologic Barrier© on Mood and Cognition (ProCog)

Cognitive Change | Mood

United Kingdom
Janssen Vaccines & Prevention B.V.
Bavarian Nordic

Terminated

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Human Papillomavirus Infections

United States, Belgium
Maastricht University Medical Center
BioActor B.V.

Completed

The Effect of Aronia Melanocarpa Extract on Cognitive Function

Cognitive Function

Netherlands
Maastricht University Medical Center
BioActor B.V.

Completed

The Effect of Berry Extract Administration on Cognitive Health

Cognitive Impairment | Overweight and Obesity

Netherlands
Erasmus Medical Center
Cardialysis B.V.; Feops

Completed

Added Value of Patient-specific Computer Simulation in Transcatheter Aortic Valve Implantation (TAVI) (TAVIguide)

Aortic Valve Stenosis

Belgium, Denmark, Germany, Italy, Netherlands
UniQure Biopharma B.V.
Chiesi Farmaceutici S.p.A.

Withdrawn

Alipogene Tiparvovec for the Treatment of LPLD Patients

LPL Deficiency

Canada, United States
Maastricht University Medical Center
FABPulous B.V.

Completed

Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome (RAPIDA)

Acute Coronary Syndrome | Thoracic Diseases | Angina Pectoris, Stable | Angina Pectoris, Unstable

Belgium, Netherlands
Alloksys Life Sciences B.V.
Aix Scientifics

Completed

Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery (APPIRED-II)

Inflammation

Netherlands
University Hospital, Brest
MCM Vaccines B.V.

Completed

Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France. (IVANHOE)

Rotavirus Gastroenteritis

France
University Medical Center Groningen
Netherlands Heart Foundation; Disphar International B.V.; Teva Nederland BV; Tiofarma... and other collaborators

Active, not recruiting

Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands (DECISION)

Heart Failure

Netherlands
Bassett Healthcare
Genentech, Inc.; Viroclinics Biosciences B.V.

Recruiting

COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1) (COMBO 1)

Influenza

United States
University Medical Center Groningen
Janssen-Cilag B.V.

Completed

A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa (HiTS)

Hidradenitis Suppurativa

Netherlands
Pharming Technologies B.V.
US Hereditary Angioedema Association

Completed

Patient Registry to Evaluate the Real-world Safety of Ruconest®

Hereditary Angioedema

United States
Radboud University Medical Center
Goodlife Fertility B.V.

Active, not recruiting

The Impact of a Nutritional Supplement (Impryl®) on Male Fertility (SUMMER)

Male Subfertility

Netherlands
Kuros Biosurgery AG
Avania; Kuros BioSciences B.V.

Active, not recruiting

KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion (STRUCTURE)

Degenerative Disc Disease | Spinal Fusion

United States
Medical University of Warsaw
Winclove Probiotics B.V.

Completed

The Effect of a Multispecies Probiotic on Reducing the Incidence of Antibiotic-associated Diarrhoea in Children.

Antibiotic-associated Diarrhea

Poland, Netherlands
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Europe B.V.

Completed

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

Healthy Volunteers

United States
University Hospital, Gentofte, Copenhagen
MCM Vaccines B.V.

Completed

The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects (Px-Lixi)

Diabetes After Total Pancreatectomy
Astellas Pharma Europe B.V.

Completed

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis (SERENITY)

Interstitial Cystitis | Bladder Pain Syndrome

Spain, Russian Federation, Belgium, Czechia, Germany, Hungary, Latvia, Netherlands, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

Healthy Subjects | Type 2 Diabetes Mellitus (T2DM) | Chronic Kidney Disease (CKD) | Pharmacokinetics of ASP8232 | Pharmacodynamics of ASP8232

Bulgaria, Moldova, Republic of, Romania
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (VIDI)

Diabetes Mellitus | Diabetic Macular Edema

United States
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
Astellas Pharma Europe B.V.

Completed

Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms (Neptune II)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Poland, Slovakia, Belarus, Germany, Czechia
Astellas Pharma Europe B.V.

Completed

A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

Type 2 Diabetes Mellitus

Germany
Astellas Pharma Europe B.V.

Completed

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (Neptune)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Hungary, Russian Federation, Poland, Slovakia, Czech Republic, Belarus, Germany
Astellas Pharma Europe B.V.

Completed

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder (Blossom)

Urinary Bladder, Overactive

Belgium, Czech Republic, Germany, Spain, Sweden, United Kingdom
Astellas Pharma Europe B.V.

Completed

An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation

Advanced Prostate Carcinoma

Russian Federation
Astellas Pharma Europe B.V.

Completed

A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects

Healthy Volunteers

United Kingdom
Astellas Pharma International B.V.

Terminated

Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) (NADIR)

Chronic Lymphocytic Leukaemia (CLL) | Indolent Non Hodgkin's Lymphoma (iNHL)

Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
Astellas Pharma Europe B.V.

Completed

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery (ONYX-3)

Venous Thromboembolism | Arthroplasty, Replacement, Hip

Denmark, Spain, United States, Austria, Colombia, Russian Federation, India, Italy, United Kingdom, Germany, Hungary, Estonia, Romania, South Africa, Israel, Poland, Sweden, Canada, Australia, Lithuania, Ukraine, Latvia, Finland, Brazil, Slovak... and more
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects

Healthy Subjects

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) (SOLAR)

Overactive Bladder | Urinary Incontinence | Urge Incontinence

France, Belgium, Spain, Turkey, Australia, Russian Federation, Hungary, Italy, Netherlands, Poland, Czech Republic
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet

Healthy Subjects | Drug-Drug Interaction (DDI)

France
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin

Healthy Subjects | Pharmacokinetics | EC905

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652

Healthy Subjects | Pharmacokinetics of ASP3652

United Kingdom
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Overactive Bladder

Poland, United Kingdom, Germany, Spain, Netherlands, Belgium, Czech Republic, Italy, Norway, Hungary, Sweden, Denmark, Greece, France, Russian Federation
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions

Healthy Subjects | Pharmacokinetics of YM178

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics

Netherlands
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

Thromboembolism

Italy, Spain, Sweden, Austria, Denmark, Russian Federation, Poland, Bosnia and Herzegovina, Serbia, Norway, Latvia, Finland, Lithuania, Czech Republic, Germany, Slovakia, Greece
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Safety

Netherlands
Catharina Ziekenhuis Eindhoven
Alloksys Life Sciences B.V.

Completed

Efficacy and Safety Study on bIAP (APPIRED)

Coronary Artery Disease | Endotoxin-mediated Complications From Cardiopulmonary Bypass Surgery

Netherlands

Clinical Trials Sponsored by TripleMed B.V.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations